Investors and security holders may obtain free copies of the registration statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Synopsys or Ansys through the website maintained by the SEC at www.sec.gov.
The documents filed by Ansys with the SEC also may be obtained free of charge at Ansys' website at https://investors.ansys.com/ or upon written request to kelsey.debriyn@ansys.com. The documents filed by Synopsys with the SEC also may be obtained free of charge at Synopsys’ website at https://investor.synopsys.com/overview/default.aspx or upon written request to Synopsys at Synopsys, Inc., 675 Almanor Avenue, Sunnyvale, California 94085, Attention: Investor Relations.
No Offer or Solicitation
This document is for informational purposes only and is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
Ansys and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.
Visit https://investors.ansys.com for more information.
ANSS-F
| Contact: | ||
| Investors: | Kelsey DeBriyn | |
| 724.820.3927 | ||
| Email Contact | ||
| Media: | Mary Kate Joyce | |
| 724.820.4368 | ||
| Email Contact |
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3384029f-4f14-40a6-aa25-bdd312e11c62
https://www.globenewswire.com/NewsRoom/AttachmentNg/6c5557bf-654c-4992-b311-b820e78249d7
https://www.globenewswire.com/NewsRoom/AttachmentNg/cc40f4a3-8d77-442d-b7dc-74867d39f672
Trailing Twelve-Month Recurring ACV
Trailing Twelve-Month Recurring ACV
Q3 2024 Trailing Twelve-Month ACV by Industry
Q3 2024 Trailing Twelve-Month ACV by Industry
Q3 2023 Trailing Twelve-Month ACV by Industry
